Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Aspirin for Stage II-III Esophageal Cancer
NCT02326779Phase 3Withdrawn
- Sponsor
- Zhejiang University
- Start
- Mar 2016
- Primary completion
- Oct 2018
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, open-label trial of aspirin in esophageal cancer (2 arms), sponsored by Zhejiang University. Primary endpoints: Disease-free survival at 5 years and Overall survival at 5 years. Planned start Mar 2016; status: withdrawn.
02
Drugs
aspirin
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT02326779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02326779.